AstraZeneca and MedImmune, its global biologics research and development arm, will present 54 abstracts, including eight oral presentations and three late breakers, to the ESMO 2018 Congress (European Society for Medical Oncology) in Munich, Germany, 19-23 October. Data span several tumour types and include full results from the Phase III SOLO-1 ovarian cancer trial to be presented in the Presidential Symposium, along with new research on resistance mechanisms in metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). In addition, MedImmune Senior Vice President, Head of Oncology Innovative Medicines and Professor of Medicine and Medical Oncology at South-Paris University, Jean-Charles Soria, will be recognised for his outstanding contribution to medical oncology by receiving the 2018 ESMO Award.
For more information: https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-presents-advances-in-improving-treatment-options-for-ovarian-and-lung-cancer-patients-at-esmo-2018-09102018.html